Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2013-05-31 Board/Management Inform…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Inleder rekrytering av ny CFO med tillträde i höst
Board/Management Information Classification · 1% confidence The document is a press release dated May 31, 2013, announcing that NeuroVive Pharmaceutical AB has started the recruitment process for a new Chief Financial Officer (CFO) because the current CFO is returning to consulting after the company's listing on Nasdaq OMX. This announcement concerns a change in senior management personnel. Based on the provided definitions, the category 'Board/Management Information (Code: MANG)' is the most appropriate fit, as it covers 'Announcement of changes in the company's board of directors or senior management.' The document length is short (2880 chars), but it is an announcement of an event (recruitment/departure), not an announcement about the publication of a separate, attached report, thus ruling out RPA/RNS based on the 'MENU VS MEAL' rule context.
2013-05-31 Swedish
NeuroVive: European phase III study approaches its final stage
Regulatory Filings Classification · 1% confidence The document is explicitly titled "NEWS RELEASE" and provides an update on the progress of clinical trials (Phase III study approaching final stage) and regulatory interactions (meeting with ANSM, application to CFDA). It is not a full financial report (10-K or IR), an earnings release (ER) which focuses on financial figures, or a formal regulatory filing like a proxy statement. Since it is a general announcement regarding company operations, clinical progress, and regulatory strategy, and does not fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Dividend (DIV), the most appropriate general category for a corporate operational update that isn't a formal financial report is the fallback category, Regulatory Filings (RNS), as it serves as a general regulatory/corporate announcement.
2013-05-29 English
NeuroVive: Europeisk fas III-studie av CicloMulsion närmar sig slutfasen
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and dated May 29, 2013. It provides an update on the progress of a Phase III clinical trial (CIRCUS study) for a drug (CicloMulsion®), mentions interactions with regulatory bodies (ANSM in France), and discusses future plans (application in China, collaboration with Quintiles). This format, focusing on key operational and clinical milestones announced to the public via a press release, strongly aligns with an Earnings Release (ER) or a general regulatory announcement. Since it is not a full financial report (10-K or IR) but rather a summary of recent operational achievements and regulatory discussions, it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were less focused on business updates. Given the content details clinical progress and regulatory strategy updates, which are common components of quarterly/periodical result announcements, ER is the most appropriate fit among the specific options, although it is not strictly a financial results announcement. However, since it is a general, time-sensitive announcement about company progress that isn't a specific report attachment notification (RPA), RNS is a strong fallback. Comparing ER and RNS: ER is for periodical financial results (often quarterly). This is a specific update outside of a standard quarterly report cycle but contains business progress. RNS is the general regulatory announcement fallback. Given the nature of the update (clinical trial progress, regulatory meetings), it functions as a significant, non-financial-specific regulatory/business update. I will classify it as RNS as it is a general regulatory announcement that doesn't fit the specific financial report categories (ER, IR, 10-K) or other specific operational categories (MANG, DIRS, etc.). The document length (6699 chars) is substantial enough that it is not just a brief announcement of another report.
2013-05-29 Swedish
Interim / Quarterly Report 2013
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT' and covers the period from 1 Jan 2013 to 31 Mar 2013. It contains detailed financial statements, including net sales, loss before tax, earnings per share, cash flow, and balance sheet information. It also includes management commentary, business highlights, and operational updates. Since it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2013
2013-05-24 English
Interim / Quarterly Report 2013
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT' (Interim Report) and covers the period from 2013-01-01 to 2013-03-31. It contains detailed financial statements, including income statements, balance sheets, cash flow analysis, and management commentary on business performance, risks, and segment information. As it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2013
2013-05-24 Swedish
NeuroVive inleder IR-satsning med Laika Consulting
Regulatory Filings Classification · 1% confidence The document is a press release dated May 8, 2013, announcing that NeuroVive Pharmaceutical AB has initiated a collaboration with Laika Consulting for Investor Relations (IR) and financial communication. It details the purpose of the collaboration (improving dialogue with shareholders and the market) and mentions immediate actions like conducting a shareholder survey. This announcement concerns changes in how the company manages its communication with investors and the market, which falls under general corporate announcements related to investor relations strategy. Since there is no specific category for 'IR Strategy Announcement,' and it is not a formal regulatory filing like 10-K, ER, or a specific transaction report, the most appropriate classification is the general regulatory/corporate announcement fallback, RNS, or potentially a category related to management/governance if the IR function is viewed as a strategic management decision. However, given the focus on communication strategy and the nature of the announcement (a press release about a new service provider), RNS (Regulatory Filings/General Announcements) is the best fit among the provided options, as it is a general corporate update that doesn't fit the more specific categories like DIV, CAP, or MANG. Given the context of IR strategy, it is a corporate communication update. I will use RNS as the general corporate announcement fallback.
2013-05-08 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.